Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
157.20
-4.32 (-2.67%)
At close: May 14, 2025, 4:00 PM
157.20
0.00 (0.00%)
After-hours: May 14, 2025, 4:36 PM EDT
Ascendis Pharma Revenue
Ascendis Pharma had revenue of 100.95M EUR in the quarter ending March 31, 2025, with 5.28% growth. This brings the company's revenue in the last twelve months to 368.70M, up 12.06% year-over-year. In the year 2024, Ascendis Pharma had annual revenue of 363.64M with 36.34% growth.
Revenue (ttm)
368.70M EUR
Revenue Growth
+12.06%
P/S Ratio
23.78
Revenue / Employee
362,538 EUR
Employees
1,017
Market Cap
9.49B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 363.64M | 96.92M | 36.34% |
| Dec 31, 2023 | 266.72M | 215.54M | 421.20% |
| Jan 1, 2023 | 51.17M | 43.40M | 557.93% |
| Dec 31, 2021 | 7.78M | 825.00K | 11.87% |
| Dec 31, 2020 | 6.95M | -6.42M | -48.01% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
ASND News
- 1 day ago - New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide) - GlobeNewsWire
- 2 days ago - New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism - GlobeNewsWire
- 9 days ago - Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025 - GlobeNewsWire
- 12 days ago - Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Ascendis Pharma Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 20 days ago - Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025 - GlobeNewsWire
- 4 weeks ago - Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory - Seeking Alpha
- 6 weeks ago - Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia - GlobeNewsWire